Skip to search formSkip to main contentSkip to account menu

amotosalen

A synthetic psoralen, light-activated DNA and RNA crosslinking agent, with protective activity against pathogens such as bacteria, viruses, protozoa… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Dermatologic AgentsFurocoumarinsPhotosensitizing Agents
amotosalen hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Amotosalen‐HCl‐UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin‐27, the cytokines that generally associate with serious adverse events
Platelets in therapeutic platelet concentrates are commonly acknowledged to release biologically active constituents during… 
2014
2014
Pathogen inactivation – defining ‘adequate’ bacterial protection
Clinical acceptance of pathogen inactivation technologies depends on the demonstration of product safety, a minimal effect on… 
2013
2013
Comparison of transfusion efficacy of amotosalen‐based pathogen‐reduced platelet components and gamma‐irradiated platelet components
Trials of transfusions of platelets (PLTs) treated with amotosalen‐based pathogen reduction (PR) showed lower corrected count… 
2012
2012
Evaluation of Pathogen Reduction Systems to Inactivate Dengue and Chikungunya Viruses in Apheresis Platelets Suspended in Plasma
The risk of blood-borne transmission of infectious diseases has led to an increasing awareness of the need for a safe and… 
2010
2010
Monitoring photochemical pathogen inactivation treatment using amotosalen and ultraviolet‐A light: evaluation of an indicator label
Until recently, prevention of transfusion–transmitted viral infections, transfusion-related sepsis and transfusion-associated… 
2009
2009
Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1‐month intravenous toxicity study in neonatal…
BACKGROUND: It is estimated that approximately 300,000 neonates undergo transfusions annually. The neonatal immune system is… 
2008
2008
Host and Donor Immune Responses Contribute to Antiviral Effects of Amotosalen-Treated Donor Lymphocytes following Early Posttransplant Cytomegalovirus Infection1
We have previously shown that amotosalen-treated splenocytes rescued allorecipients from a lethal dose of mouse CMV (MCMV… 
2008
2008
Photochemical Pathogen Inactivation Treatment of Human Plasma (amotosalen + UVA) Has No Major Impact on the Protein expression pattern Assessed by a 2-DIGE Proteomic Assay.
Background: Photochemical treatment (PCT) using amotosalen HCl and UVA light (3 J/cm 2 : 320 – 400 nm) inactivates pathogens and… 
2005
2005
The Efficacy of Photochemical Treatment with Amotosalen and UVA (INTERCEPT) for Inactivation of T. cruzi In Buffy Coat Platelet Components.
Introduction.Transfusion-associated Chagas’ disease has been transmitted by labile blood components in endemic countries. In… 
2004
2004
In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen
Recent studies by van Rhenen et al. found that platelets treated with amotosalen hydrochloride and ultraviolet A (UVA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)